Kolon Life Science is facing more headwinds on its gene therapy for degenerative arthritis as a Japanese partner seeks to cancel a license deal signed last year due to negligent reporting on issues related to the late-stage drug candidate.
Kolon Life Science is facing more headwinds on its gene therapy for degenerative arthritis as a Japanese partner seeks to cancel a license deal signed last year due to negligent reporting on issues related to the late-stage drug candidate.
Mitsubishi Tanabe Pharma has started negotiations with Kolon, which holds the Asia license of the drug Invossa-K Inj. developed by its US-based affiliate TissueGene, to terminate the agreement, according to the Korean firm on Dec. 20.
